• Increase Font

    Sofosbuvir reduces transplant rate in HCV patients

    Patients infected with hepatitis C virus (HCV) who have decompensated liver disease should be treated with a sofosbuvir-based regimen, according to a new study.

    Direct-acting antiviral agents (DAAs) have transformed the treatment of chronic HCV infection. However, the impact of treating with DAAs versus no treatment on key outcomes in patients with decompensated cirrhosis has not been well defined.

    “This is the first study to demonstrate the impact of DAAs in this sick population in the context of multiple clinical trials and comparing to a group of control patients who were not treated,” senior author Michael Charlton, MD, associate director of Intermountain Medical Center Transplant Program in Salt Lake City, Utah, told Medical Economics.

    The researchers presented the results at the in Prague, Czech Republic.

    Next: Study details


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow